دورية أكاديمية
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β 2 -agonist use in asthma.
| العنوان: | SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β |
|---|---|
| المؤلفون: | Cabrera CS; AstraZeneca, Gothenburg, Sweden.; Dept of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.; Co-first authors., Nan C; AstraZeneca, Gothenburg, Sweden cassandra.nan@astrazeneca.com.; Co-first authors., Lindarck N; AstraZeneca, Södertälje, Sweden., Beekman MJHI; AstraZeneca, The Hague, The Netherlands., Arnetorp S; AstraZeneca, Gothenburg, Sweden., van der Valk RJP; AstraZeneca, Cambridge, UK. |
| المصدر: | The European respiratory journal [Eur Respir J] 2020 Feb 12; Vol. 55 (2). Date of Electronic Publication: 2020 Feb 12 (Print Publication: 2020). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Sheffield, United Kingdom : European Respiratory Society Original Publication: Copenhagen : Published jointly by the Society and Munksgaard, 1988- |
| مواضيع طبية MeSH: | Asthma*/drug therapy, Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/therapeutic use ; Adrenergic beta-Agonists/therapeutic use ; Humans ; Prescriptions |
| مستخلص: | Competing Interests: Conflict of interest: C.S. Cabrera is an employee of AstraZeneca. Conflict of interest: C. Nan is an employee of AstraZeneca, and holds shares in AstraZeneca and GlaxoSmithKline. Conflict of interest: N. Lindarck is an employee of AstraZeneca. Conflict of interest: M.J.H.I. Beekman is an employee of AstraZeneca. Conflict of interest: S. Arnetorp is an employee of AstraZeneca. Conflict of interest: R.J.P. van der Valk is an employee of AstraZeneca, and was formerly employed by and holds shares in GlaxoSmithKline. |
| المشرفين على المادة: | 0 (Adrenergic beta-2 Receptor Agonists) 0 (Adrenergic beta-Agonists) |
| تواريخ الأحداث: | Date Created: 20191207 Date Completed: 20210621 Latest Revision: 20210621 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1183/13993003.01858-2019 |
| PMID: | 31806716 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1399-3003 |
|---|---|
| DOI: | 10.1183/13993003.01858-2019 |